FDA Investigator: Wendy G. Tan

- Wendy G. Tan first started conducting FDA inspections in 2017, with the last inspection in 2023. Over that time, Wendy G. Tan has conducted 20 inspections at 20 companies across 20 sites.

Documents

FDA 483 Evive Biopharmaceutical (Beijing), Ltd., Beijing | 2023

Out-of-stock
Wendy G. Tan
Human Drugs Form 483

FDA 483 Suzhou Union Biopharm Co., Ltd., Suzhou | 2023

Out-of-stock
Wendy G. Tan
Human Drugs Form 483

FDA 483 Rentschler Biopharma Inc., Milford | 2023

Out-of-stock
Wendy G. Tan
Human Drugs Form 483

FDA 483 Rentschler Biopharma SE, Laupheim | 2023

Out-of-stock
Wendy G. Tan
Human Drugs Form 483

FDA 483 Vetter Pharma Fertigung GmbH & Co. KG, Langenargen | 2023

Out-of-stock
Wendy G. Tan
Human Drugs Form 483

FDA 483 Lilly France S.A.S., Fegersheim | 2022

Out-of-stock
Wendy G. Tan
Human Drug Form 483

FDA 483 Biogen U.S. Corporation, Research Triangle Park | 2022

Out-of-stock
Wendy G. Tan
Human Drug Form 483

FDA 483 Roche Singapore Technical Operations Pte. Ltd., Singapore | 2022

Out-of-stock
Wendy G. Tan
Human Drug Form 483

FDA 483 SEAGEN INC., Bothell | 2022

Out-of-stock
Wendy G. Tan
Human Drug Form 483

FDA 483 Lyocontract GmbH, Ilsenburg (Harz) | 2022

Out-of-stock
Wendy G. Tan
Human Drug Form 483

FDA 483 Kashiv BioSciences, LLC, Chicago | 2022

Out-of-stock
Wendy G. Tan
Human Drug Form 483

FDA 483 MSD International GmbH, Singapore | 2021

Out-of-stock
Wendy G. Tan
Human Drug Form 483

FDA 483 Rafa Laboratories Ltd., Jerusalem | 2017

Out-of-stock
Wendy G. Tan
Human Drug Form 483

FDA 483 Bausch & Lomb, Inc. a Division of Valeant Pharmaceuticals, Tampa | 2017

Out-of-stock
Wendy G. Tan
Human Drug Form 483